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On page 30, [Table 1](#t1-jaa-8-135){ref-type="table"} was incorrect. The corrected table is shown below.

On page 31, [Tables 2](#t2-jaa-8-135){ref-type="table"} and [3](#t3-jaa-8-135){ref-type="table"} were incorrect. The corrected tables are shown below.

On page 33, [Figure 3](#f3-jaa-8-135){ref-type="fig"} was incorrect. The corrected figure is shown below.

![Evolution of total symptoms score (5TSS): **A**) morning evaluation for the 5TSS scores during study period; **B**) evening evaluation for the 5TSS scores during the study period](jaa-8-135Fig3){#f3-jaa-8-135}

###### 

Demographic and clinical characteristics at baseline in ITT population

  Variable            Placebo   Rupatadine 10 mg   Rupatadine 20 mg   Cetirizine 10 mg
  ------------------- --------- ------------------ ------------------ ------------------
  Gender (male%)      27 (38)   18 (27)            26 (37)            28 (41)
  Age (years)         30.9      31.4               33.8               32.2
  Race (caucasian%)   69 (97)   65 (100)           68 (100)           63 (92)
  5TSS mean value     8.80      8.75               8.10               8.39
  4NTSS mean value    7.67      7.38               7.07               7.23

**Notes:** 5TSS: total symptoms score was calculated by adding the 5 symptom scores: rhinorrhea, sneezing, nasal itching, nasal obstruction, and conjunctival itching; 4NTSS: total nasal symptoms score was calculated by adding the 4 symptom scores: rhinorrhea, sneezing, nasal itching, and nasal obstruction. No significant differences were found between treatment groups.

###### 

Summary of morning (morning reflective) total symptoms score (5TSS) and nasal total symptoms score (4NTSS) assessments (ITT population)

                                            Placebo   Rupatadine 10 mg                                     Rupatadine 20 mg                                     Cetirizine 10 mg                                     ANOVA                                                                                                                                                                    
  -------------------------------- -------- --------- ---------------------------------------------------- ---------------------------------------------------- ---------------------------------------------------- ---------------------------------------------------- ---------------------------------------------------- ---------------------------------------------------- --------- ---------
  Baseline                         5TSS     8.80      0.26                                                 8.75                                                 0.27                                                 8.10                                                 0.23                                                 8.39                                                 0.24      NS
  4NTSS                            7.67     0.21      7.38                                                 0.22                                                 7.07                                                 0.20                                                 7.23                                                 0.18                                                 NS        
  2 weeks                          5TSS     5.74      0.46                                                 4.18[\*\*](#tfn3-jaa-8-135){ref-type="table-fn"}     0.34                                                 3.04[\*\*](#tfn3-jaa-8-135){ref-type="table-fn"}     0.28                                                 3.38[\*\*](#tfn3-jaa-8-135){ref-type="table-fn"}     0.32      \<0.001
  4NTSS                            5.10     0.39      3.63[\*\*](#tfn3-jaa-8-135){ref-type="table-fn"}     0.29                                                 2.75[\*\*](#tfn3-jaa-8-135){ref-type="table-fn"}     0.25                                                 2.92[\*\*](#tfn3-jaa-8-135){ref-type="table-fn"}     0.27                                                 \<0.001   
  4 weeks                          5TSS     5.57      0.42                                                 3.61[\*\*](#tfn3-jaa-8-135){ref-type="table-fn"}     0.41                                                 2.82[\*\*](#tfn3-jaa-8-135){ref-type="table-fn"}     0.28                                                 3.85[\*\*](#tfn3-jaa-8-135){ref-type="table-fn"}     0.38      \<0.001
  4NTSS                            5.00     0.36      3.14[\*\*](#tfn3-jaa-8-135){ref-type="table-fn"}     0.36                                                 2.54[\*\*](#tfn3-jaa-8-135){ref-type="table-fn"}     0.26                                                 3.23[\*\*](#tfn3-jaa-8-135){ref-type="table-fn"}     0.30                                                 \<0.001   
  change from baseline (4 weeks)   5TSS     −3.23     0.44                                                 −5.20[\*\*](#tfn3-jaa-8-135){ref-type="table-fn"}    0.46                                                 −5.21[\*\*](#tfn3-jaa-8-135){ref-type="table-fn"}    0.32                                                 −4.55[\*](#tfn2-jaa-8-135){ref-type="table-fn"}      0.37      0.001
  4NTSS                            −2.67    0.37      −4.28[\*\*](#tfn3-jaa-8-135){ref-type="table-fn"}    0.41                                                 −4.48[\*\*](#tfn3-jaa-8-135){ref-type="table-fn"}    0.29                                                 −4.00[\*\*](#tfn3-jaa-8-135){ref-type="table-fn"}    0.32                                                 0.001     
  \% change from baseline          5TSS     −34.76    5.09                                                 −57.93[\*\*](#tfn3-jaa-8-135){ref-type="table-fn"}   4.79                                                 −64.34[\*\*](#tfn3-jaa-8-135){ref-type="table-fn"}   3.55                                                 −54.75[\*\*](#tfn3-jaa-8-135){ref-type="table-fn"}   4.17      \<0.001
  4NTSS                            −33.17   5.07      −55.92[\*\*](#tfn3-jaa-8-135){ref-type="table-fn"}   5.13                                                 −63.51[\*\*](#tfn3-jaa-8-135){ref-type="table-fn"}   3.70                                                 −54.95[\*\*](#tfn3-jaa-8-135){ref-type="table-fn"}   4.02                                                 \<0.001   

**Notes:**

*P*\<0.05 vs placebo;

*P*\<0.01 vs placebo.

**Abbreviation:** NS, not significant.

###### 

Summary of evening (evening reflective) total symptoms score (5TSS) assessments and nasal total symptoms score (4NTSS) (ITT population)

                                            Placebo   Rupatadine 10 mg                                     Rupatadine 20 mg                                     Cetirizine 10 mg                                     ANOVA                                                                                                                                                                     
  -------------------------------- -------- --------- ---------------------------------------------------- ---------------------------------------------------- ---------------------------------------------------- ---------------------------------------------------- ---------------------------------------------------- ---------------------------------------------------- ---------- ----------
  Baseline                         5TSS     8.80      0.26                                                 8.75                                                 0.27                                                 8.10                                                 0.23                                                 8.39                                                 0.24       NS
  4NTSS                            7.67     0.21      7.38                                                 0.22                                                 7.07                                                 0.20                                                 7.23                                                 0.18                                                 NS         
  2 weeks                          5TSS     5.10      0.45                                                 3.74[\*\*](#tfn6-jaa-8-135){ref-type="table-fn"}     0.32                                                 3.01[\*\*](#tfn6-jaa-8-135){ref-type="table-fn"}     0.27                                                 3.14[\*\*](#tfn6-jaa-8-135){ref-type="table-fn"}     0.31       \< 0.001
  4NTSS                            4.53     0.38      3.29[\*\*](#tfn6-jaa-8-135){ref-type="table-fn"}     0.29                                                 2.68[\*\*](#tfn6-jaa-8-135){ref-type="table-fn"}     0.23                                                 2.68[\*\*](#tfn6-jaa-8-135){ref-type="table-fn"}     0.27                                                 \< 0.001   
  4 weeks                          5TSS     5.47      0.42                                                 3.41[\*\*](#tfn6-jaa-8-135){ref-type="table-fn"}     0.37                                                 2.76[\*\*](#tfn6-jaa-8-135){ref-type="table-fn"}     0.28                                                 3.35[\*\*](#tfn6-jaa-8-135){ref-type="table-fn"}     0.36       \< 0.001
  4NTSS                            4.89     0.37      2.98[\*\*](#tfn6-jaa-8-135){ref-type="table-fn"}     0.32                                                 2.50[\*\*](#tfn6-jaa-8-135){ref-type="table-fn"}     0.25                                                 2.82[\*\*](#tfn6-jaa-8-135){ref-type="table-fn"}     0.29                                                 \< 0.001   
  change from baseline (4 weeks)   5TSS     −3.33     0.45                                                 −5.41[\*\*](#tfn6-jaa-8-135){ref-type="table-fn"}    0.43                                                 −5.34[\*\*](#tfn6-jaa-8-135){ref-type="table-fn"}    0.35                                                 −5.05[\*\*](#tfn6-jaa-8-135){ref-type="table-fn"}    0.35       \<0.001
  4NTSS                            −2.79    0.39      −4.44[\*\*](#tfn6-jaa-8-135){ref-type="table-fn"}    0.37                                                 −4.57[\*\*](#tfn6-jaa-8-135){ref-type="table-fn"}    0.31                                                 −4.41[\*\*](#tfn6-jaa-8-135){ref-type="table-fn"}    0.31                                                 \<0.001    
  \% change from baseline          5TSS     −35.98    5.14                                                 −60.11[\*\*](#tfn6-jaa-8-135){ref-type="table-fn"}   4.35                                                 −64.56[\*\*](#tfn6-jaa-8-135){ref-type="table-fn"}   3.61                                                 −60.62[\*\*](#tfn6-jaa-8-135){ref-type="table-fn"}   3.88       \<0.001
  4NTSS                            −34.65   5.22      −58.20[\*\*](#tfn6-jaa-8-135){ref-type="table-fn"}   4.49                                                 −63.65[\*\*](#tfn6-jaa-8-135){ref-type="table-fn"}   3.66                                                 −61.05[\*\*](#tfn6-jaa-8-135){ref-type="table-fn"}   3.76                                                 \<0.001    

**Notes:**

*P*\<0.05 vs placebo;

*P*\<0.01 vs placebo.

**Abbreviation:** NS, not significant.
